Abstract
Background: Chemotherapy is the most current alternative treatment that requires many resources and long-term arrangements. All stages of lymphoma cancer use this therapeutic modality. The costs become a financial burden for patients, families, service providers, and the government. Objective: This study aims to estimate the economic burden and measure the adequacy of national tariffs for lymphoma cancer patients’ chemotherapy. Method: This research is a cost analysis study examining retrospective data. The analysis uses a prevalence approach and bottom-up processes. The secondary data comprises treatment and claim costs borne by lymphoma cancer patients undergoing chemotherapy at a teaching hospital in Indonesia from May 2020 to May 2021. Quantitative analysis was used to calculate the cost of illness. Results: The data shows that the economic burden of 55 lymphoma cancer patients receiving chemotherapy was USD 38,958.70 per year. Lymphoma patients paid USD 708.34 or about one-six GDP for each chemotherapy visit. The margin between the value of insurance claims and medical costs is from USD 8.41 to 110.51. Conclusion: The economic burden for lymphoma chemotherapy is unreasonable, but the revenue from the national tariffs is minimal. Hence, the government should promote prevention programmes more than curative ones to minimise lymphoma cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
